Individualizing Treatment for Chronic Rhinosinusitis with Nasal Polyps: Novel Options for Optimizing Outcomes – Clinical Review

November 15, 2021 - November 14, 2022

Overview

Overview

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic condition associated with multiple comorbidities and decreased quality of life. It is a condition characterized by inflammation of the sinonasal mucosa and clinical symptoms including blocked nose, rhinorrhea, hyposmia or anosmia, and pain or pressure in the face. Advances in understanding of the underlying pathology for CRSwNP has resulted in novel immunomodulatory biologic therapies for its treatment.

In the second of a 2-part series, this text-based activity will offer learners an in-depth review of the clinical data with biologic therapies for the treatment of CRSwNP.

Target Audience

Physician specialists (allergists, immunologists, ENTs) and primary care providers who may treat patients with CRSwNP.

Learning Objectives

  1. Evaluate the mechanism of action, safety, and efficacy of biologics for the treatment of chronic rhinosinusitis with nasal polyps

Activity Launch Date – November 15, 2021
Expiration Date – November 14, 2022

Agenda

Time Description

Pre-Test

DynamicEd Clinical Review

Post-Test

Final Evaluation

Faculty & Disclosures


Faculty

Anju Tripathi Peters, MD, MS
Professor, Department of Medicine
Director of Clinical Research, Division of Allergy-Immunology
Medical Director, Northwestern Medicine Clinical Research Unit
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty Disclosures

Dr Anju T. Peters, MD has received research funding from AstraZeneca, Optinose, and Sanofi Regeneron; served on Advisory Board for AstraZeneca and Sanofi Regeneron; and served as a Consultant for GSK and Optinose during the past 24 months.*

*Horizon CME has mitigated and resolved all relevant financial relationships

Planner Disclosures

Those involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.

Other Contributor Disclosures

All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients during the past 24 months.

CME Information

Activity Launch Date - 11/15/21
Expiration Date - 11/14/22

AMA PRA Category 1 Credit(s)

Accreditation Statement
Horizon CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Horizon CME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


How to obtain credit for attendance (eligibility requirement and process for obtaining certificate)

To receive documentation of credit, participants must:

  1. Read the CME/CE information, learning objectives, and faculty disclosures
  2. Complete the Pre-Test
  3. Participate in the Activity
  4. Complete the Post-test
  5. Complete the online evaluation form
    The last day to access the evaluation is November 14, 2022 at 11:59pm (Pacific Time)*
  6. Attest to the time in attendance to generate your certificate

*Requests from learners to claim credit after the evaluation closes will not be granted

Please email info@horizoncme.com should you have any issues.


Copyright Information
Copyright © 2021 by Horizon CME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME.

Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Disclosure of Unlabeled Use
Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Statement of Independence
Per ACCME, AMA and FDA regulations, it is understood that commercial supporters will have no influence on the content of the activity. Horizon CME will ensure an unbiased presentation and provide full disclosure of relationships between Horizon CME and all commercial supporters and any significant financial interest or other relationship between faculty and manufacturers of commercial products discussed in the activities. No faculty proposed in this grant is an employee, shareholder, owner, or has financial interest in the accrediting power. It is understood that commercial support funding of this activity is not in any way conditioned upon any present or future business relationship

Any questions? Please check out our FAQs section or feel free to contact us.

Excellent. We’ll need to sort out a few details.

* How did you hear about this activity?